METHOD OF TREATMENT OF ATTENTION-DEFECIT/HUPERACTIVITY DISORDER

摘要

1. A use of a compound of the formula wherein X = C1-C4 alkylthio, and Y = C1-C4 alkyl or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof for the treatment of attention-deficit/huperactivity disorder of duloxetine. 2. A use of claim 1 wherein the predominantly inattentive type of attention-deficit/hyperactivity disorder is to be treated. 3. A use of claim 1 wherein the predominantly hyperactive-impulsive type of attention-deficit/hyperactivity disorder is to be treated. 4. A use of claim 1 wherein the combined type of attention-deficit/hyperactivity disorder is to be treated. 5. A use of claim 1 wherein the patient to be treated is a child. 6. A use of claim 1 wherein the patient to be treated is an adolescent. 7. A use of claim 1 wherein the patient to be treated is an adult. 8. A use of a compound of the formula wherein X = C1-C4 alkylthio, and Y = C1-C4 alkyl or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of attention-deficit/hyperactivity disorder of duloxetine. 9. A use of claim 8 wherein the predominantly inattentive type of attention-deficit/hyperactivity disorder is to be treated. 10. A use of claim 8 wherein the predominantly hyperactive-impulsive type of attention-deficit/hyperactivity disorder is to be treated. 11. A use of claim 8 wherein the combined type of attention-deficit/hyperactivity disorder is to be treated. 12. A use of claim 8 wherein the patient to be treated is a child. 13. A use of claim 8 wherein the patient to be treated is an adolescent. 14. A use of claim 8 wherein the patient to be treated is an adult. 15. A use of a pharmaceutical composition comprising a pharmaceutical carrier and a compound of the formula I wherein X = C1-C4 alkylthio, and Y = C1-C4 alkyl or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof for the treatment of attention-deficit/hyperactivity disorder. 16. A composition of claim 15 wherein the predominantly inattentive type of attention-deficit/hyperactivity disorder is to be treated. 17. A composition of claim 15 wherein the predominantly hyperactive-impulsive type of attention-deficit/hyperactivity disorder is to be treated. 18. A composition of claim 15 wherein the combined type of attention-deficit/hyperactivity disorder is to be treated. 19. A composition of claim 15 wherein the patient to be treated is a child. 20. A composition of claim 15 wherein the patient to be treated is an adolescent. 21. A composition of claim 15 wherein the patient to be treated is an adult. 22. A use of any one of claims 1-14 wherein the compound is N-methyl-3-(2-methylthiophenoxy)-3-phenylpropylamine or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. 23. A use of any one of claims 15-21 wherein the compound is N-methyl-3-(2-methylthiophenoxy)-3-phenylpropylamine or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof.